HS
PRAX icon

HighVista Strategies’s Praxis Precision Medicines PRAX Stock Holding History

HighVista Strategies’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1M Buy
30,210
+3,887
+15% +$1.23M 2.31% 6
2026
Q1 		$8.48M Buy
26,323
+482
+2% +$149K 2.34% 3
2025
Q4 		$7.62M Sell
25,841
-69,161
-73% -$12.9M 1.96% 7
2025
Q3 		$5.04M Buy
95,002
+27,714
+41% +$1.34M 1.23% 20
2025
Q2 		$2.83M Buy
67,288
+28,002
+71% +$1.07M 1.04% 22
2025
Q1 		$1.49M Buy
39,286
+28,335
+259% +$1.77M 0.57% 70
2024
Q4 		$843K Hold
10,951
– – 0.31% 107
2024
Q3 		$630K Buy
+10,951
New +$592K 0.22% 110

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

HighVista Strategies's PRAX Position: Q2 2026 in Review

HighVista Strategies increased its Praxis Precision Medicines (PRAX) stake by 15% in Q2 2026, buying an estimated $1.23M and bringing the position to 30,210 shares worth $10.1M. The position accounts for 2.31% of the portfolio, ranked #6.

HighVista Strategies first reported a position in PRAX in Q3 2024 and has held it in 8 quarters since. 310 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • HighVista Strategies held 30,210 shares of Praxis Precision Medicines worth $10.1M as of Q2 2026.
  • HighVista Strategies bought 3,887 Praxis Precision Medicines shares in Q2 2026, an estimated $1.23M.
  • Praxis Precision Medicines made up 2.31% of HighVista Strategies's portfolio in Q2 2026, its #6 holding.
  • HighVista Strategies first reported a position in Praxis Precision Medicines in Q3 2024 and has held it in 8 quarters since.
  • 310 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.